Intraperitoneal chemotherapy, involving the administration of certain chemotherapeutic agents directly to the intraperitoneal cavity, was developed as a novel therapeutic strategy early in the 1950s. Intraperitoneal administration of chemotherapy results in higher intraperitoneal concentration of the cytotoxic medications and minimal systemic exposure than observed with intravenous administration, which in turn may increase the efficacy of these agents with substantial reduction in systemic toxicity. Intraperitoneal chemotherapy was used successfully in peritoneal surface malignancies, including malignant peritoneal mesothelioma, pseudomyxoma peritonei, malignant ascites, sarcomatosis, and peritoneal carcinomatosis from gastrointestinal and ovarian cancers. Pharmacists may play a major role in optimizing intraperitoneal chemotherapy through verification of chemotherapy order for proper doses, dilution, preparation, and administration. Moreover, pharmacists are medication experts who can provide other health care professionals with the necessary drug information.
Despite the local application of chemotherapy, intraperitoneal chemotherapy is not free of systemic side effects and can be associated with serious complications. The benefits of intraperitoneal chemotherapy should be weighed against its potential harm to maximize efficacy and to minimize morbidity and mortality as much as possible. The aim of this article is to review the current available literature regarding the safety and efficacy of intraperitoneal chemotherapy in cancer treatment.
Maurie MarkmanMD. Advances in peritoneal surface oncology: Intraperitoneal chemotherapy in the management of ovarian cancer. Recent Res Cancer Res2009; 169: 165–176.
2.
VermorkenJB. Intraperitoneal chemotherapy in advanced ovarian cancer: Recognition at last. Ann Oncol2006; 17(Suppl 10): 241–246.
3.
MacriA. New approach to peritoneal surface malignancies. World J Gastrointest Oncol2010; 2(1): 9–11.
4.
GoldsteinPGomes da SilvaRCabanasJ. Management of peritoneal carcinomatosis from colon cancer, gastric cancer and appendix malignancy. Cancer Ther2005; 3: 299–320.
5.
Gonzalez-MorenoSGonzalez-BayonLAOrtega-PerezG. Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol2010; 2(2): 68–75.
JaabackKJohnsonNLawrieTA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev2011; 11: Art. No. CD005340–Art. No. CD005340.
8.
Tentes AAK, Spiliotis ID, Korakianitis OS, et al. Adjuvant perioperative intraperitoneal chemotherapy in locally advanced colorectal carcinoma: Preliminary results. ISRN Surgery 2011; article ID 529876, 6pp. DOI: 10.5402/2011/529876.
9.
ColeyWB. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Clin Orthop Relat Res1991; 262: 3–11.
10.
RamponeBSchiavoneBMartinoA. Current role of hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from colorectal cancer. World J Gastroenterol2010; 16(11): 1299–1302.
11.
OakninARodaDGonzalez-MartinA. Feasibility of a modified outpatient regimen of intravenous/intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients: A GEICO study. Int J Gynecol Cancer2011; 21(6): 1048–1055.
12.
SeamonLGCarlsonMJRichardsonDL. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer2009; 19(7): 1195–1198.
13.
CashinPHGrafWNygrenP. Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: A case-control study. Ann Oncol2012; 23(3): 647–652.
14.
CooksleyTJHaji-MichaelP. Post-operative critical care management of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). World J Surg Oncol2011; 9: 169–169.
15.
EliasDBenizriEDi PietrantonioD. Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol2007; 14(2): 509–514.
16.
SarnaikAASussmanJJAhmadSA. Technology of intraperitoneal chemotherapy administration: A survey of techniques with a review of morbidity and mortality. Surg Oncol Clin N Am2003; 12(3): 849–863.
17.
WademanMHaJSinghH. Current indications, techniques and results of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for intra-abdominal malignancies. Surg Curr Res2012; 2: 125–125.
18.
Fung-Kee-Fung M, Provencher D, Rosen B, et al. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: A review of the evidence and standards for the delivery of care. Gynecol Oncol Epub ahead of print 2007. DOI: 10.1016/j.ygyno.2007.02.015.
YanTDCaoCQMunkholm-LarsenS. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol2010; 2(2): 109–116.
21.
EliasDBonnayMPuizillouJM. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol2002; 13: 267–272.
22.
ChanDLMorrisDLRaoA. Intraperitoneal chemotherapy in ovarian cancer: A review of tolerance and efficacy. Cancer Manage Res2012; 4: 413–422.
23.
MohamedFSugarbakerPH. Intraperitoneal taxanes. Surg Oncol Clin N Am2003; 12: 825–833.
24.
de BreeETsiftsisDD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Res Cancer Res2007; 169: 39–51.
25.
de BreeETsiftsisDD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: From laboratory bench to bedside. Recent Res Cancer Res2007; 169: 53–73.
26.
SugarbakerPHMoraJTCarmignaniP. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy. Oncologist2005; 10: 112–122.
Sugarbaker PH, Stuart OA and Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: Rationale and report of early data. Int J Surg Oncol Epub ahead of print 2011; 2011. DOI: 10.1155/2011/161862.
29.
StuartOAStephensADWelchL. Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C. Ann Surg Oncol2002; 9: 186–191.
30.
González-BayónLGonzález-MorenoSOrtega-PérezG. Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. Eur J Surg Oncol2006; 32: 619–624.
31.
HelmCW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist2009; 14: 683–683.
MarkmanMWalkerJL. Intraperitoneal chemotherapy of ovarian cancer: A review, with a focus on practical aspects of treatment. J Clin Oncol2006; 24(6): 988–994.
34.
JaabackKJohnsonNLawrieTA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev2011; 11: Art. No. CD005340–Art. No. CD005340.
35.
ArmstrongDKBundyBWenzelL. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med2006; 354: 34–34.
BevanKEMohamedFMoranBJ. Pseudomyxoma peritonei. World J Gastrointest Oncol2010; 2(1): 44–50.
38.
ChuaTCMoranBJSugarbakerPH. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol2012; 30: 2449–2456.
39.
StewartJH4thShenPRusselGB. Appendiceal neoplasms with peritoneal dissemination: Outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol2006; 13: 624–634.
WoopenHSehouliJ. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res2009; 29: 3353–3360.
42.
LinkKHRoitmanMHoltappelsM. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surg Oncol Clin N Am2003; 12(3): 865–872.
43.
LoggieBWPeriniMFlemingRA. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg1997; 63: 137–143.
44.
BitranJD. Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. Cancer1985; 56: 2420–2423.
45.
GarofaloAValleMGarciaJ. Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol2006; 32: 682–685.
46.
HeissMMMurawaPKoralewskiP. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer2010; 127(9): 2209–2221.
47.
KhatriVP. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A panacea or just an obstacle course for the patient?J Clin Oncol2010; 28(1): 5–7.
48.
SugarbakerPH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol2007; 95: 93–96.
49.
VerwaalVJvan RuthSde BreeE. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol2003; 21: 3737–3743.
50.
VerwaalVJBruinSBootH. 8-years follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol2008; 15: 2426–2432.
RadulescuCTufeanuDMintioanC. Intraperitoneal chemotherapy for advanced gastric cancer. TMJ2009; 59(1): 49–55.
53.
YanTDBlackDSugarbakerPH. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol2007; 14(10): 2702–2713.
54.
SunJSongYWangZ. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: A meta-analysis of the randomized controlled trials. BMC Cancer2012; 12: 526–526.
YanTDBlackDSavadyR. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol2007; 18: 827–834.
57.
EliasDBedardVBouzidT. Malignant peritoneal mesothelioma: Treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy. Gastroenterol Clin Biol2007; 31(10): 784–788.
58.
SugarbakerPHWelchLSMohamedF. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am2003; 12: 605–621.
59.
CeelenWPPahlmanLMahtemeH. Pharmacodynamic aspects of intraperitoneal cytotoxic therapy. Cancer Treat Res2007; 134: 195–195.
60.
FeldmanALLibuttiSKPingpankJF. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol2003; 21: 4560–4560.
61.
YanTDDeracoMBarattiD. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience. J Clin Oncol2009; 27: 6237–6242.
62.
GamblinTCEqorinMJZuhowskiEG. Intraperitoneal gemcitabine pharmacokinetics: A pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas. Cancer Chemother Pharmacol2008; 62: 647–653.
63.
OeiTNJaqannathanJPRamaiyaN. Peritoneal sarcomatosis versus peritoneal carcinomatosis: Imaging findings at MDCT. Am J Roentgenol2010; 195: 229–235.
64.
BerthetBSugarbakerTAChangD. Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment. Eur J Cancer1999; 35(3): 413–419.
65.
de BreeEZoetmulderFANRomanosJ. Intraperitoneal chemotherapy for prevention and treatment of peritoneal carcinomatosis from colorectal origin. Ann Gastroenterol2003; 16(1): 20–33.
66.
AlbertsDSLiuPYHanniganEV. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med1996; 335: 1950–1955.
67.
TuttleTMZhangYGreenoE. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol2006; 13(12): 1627–1632.
68.
YuWWhangISuhI. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg1998; 228(3): 347–354.
69.
SunVOtis-GreenSMorganR. Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer. Eur J Oncol Nurs2013; 17(3): 375–380.
